The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …

Cancer progression involves the gradual loss of a differentiated phenotype and acquisition
of progenitor and stem-cell-like features. Here, we provide novel stemness indices for …

Metabolic reprogramming, especially Warburg effect, is a key event in tumor initiation and
progression. ZEB1 plays a vital role in metastasis of various cancers. We previously found …

Therapeutic attempts to treat hepatocellular carcinoma (HCC) frequently result in a poor
response or treatment failure. The efficacy of approved drugs and survival expectancies is …

Molecular signaling pathways involved in cancer have been intensively studied due to their
crucial role in cancer cell growth and dissemination. Among them, zinc finger E-box binding …

MicroRNAs (miRNAs), a class of emerging small non-coding RNAs, serve as vital players in
modulating multiple biological processes via the post-transcriptional regulation of gene …

Alpha fetoprotein (AFP) is the most widely used diagnostic and prognostic serum biomarker
for hepatocellular carcinoma (HCC). Despite its wide clinical use, a systematic …

Hepatocellular carcinoma (HCC) is one of the most common malignant cancers and
currently the third leading cause of cancer-related deaths, worldwide. Epithelial …

Hepatocellular carcinoma (HCC) ranks the third leading cause of cancer death in the world
and has a notably low survival rate. Circular RNAs (circRNAs) are newly classed non-coding …